Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years tags : Ema save search
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
Published: 2024-03-28 (Crawled : 12:30) - prnewswire.com
PTCT | News S | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 0.14%
H: 1.19%
C: -1.32%
treatment ema submission
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 0.45%
H: 3.29%
C: 0.53%
metabolic cirrhosis treatment fibrosis prime ema
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: -0.86%
H: 2.04%
C: 1.66%
liver authorization treatment fibrosis pharmaceuticals ema application
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $42.19 -0.14% -0.14% 530K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: 8.46%
H: 35.96%
C: 29.21%
st-920 fda disease approval prime ema therapeutics potential
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2024-02-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
treatment ema
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Published: 2023-12-17 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.7%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.79%
H: 0.35%
C: -0.26%
UVV | $51.46 1.9% 0.0% 190K
|
Consumer Non-Durables
|
| O: 0.0%
H: 0.05%
C: -1.86%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.09%
H: 1.41%
C: 0.52%
children treatment ema
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
Published: 2023-12-15 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
first positive treatment ema africa
EMA Requests More Data from GLP-1 Drugmakers in Suicidal Ideation, Self-Harm ...
Published: 2023-12-04 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -0.41%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
ema
EMA Requests More Data from GLP-1 Drugmakers in Suicidal Ideation, Self-Harm Probe
Published: 2023-12-04 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -0.41%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
ema
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 6.31%
H: 2.24%
C: 1.34%
fda ema program
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Published: 2023-11-27 (Crawled : 12:00) - globenewswire.com
KRYS | $158.63 -3.26% -3.37% 340K
|
Health Technology
|
| O: 1.87%
H: 0.05%
C: -3.94%
vyjuvek biotech authorization treatment ema application
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
Published: 2023-11-16 (Crawled : 13:00) - globenewswire.com
PRAX | $46.88 0.62% 0.62% 350K
|
Health Technology
|
| O: 2.06%
H: 4.04%
C: -2.97%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: -2.69%
prax-222 treatment designation prime ema
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
Published: 2023-10-24 (Crawled : 11:00) - globenewswire.com
ANNX | $4.57 2.93% 2.84% 1.2M
|
Health Technology
|
| O: 3.57%
H: 10.92%
C: 4.6%
anx007 treatment designation prime ema
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: -0.89%
H: 2.49%
C: -0.3%
genetic treatment designation ema
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
Published: 2023-09-29 (Crawled : 23:00) - biospace.com/
GERN | $3.69 -1.07% -1.08% 8.2M
|
Health Technology
|
| O: 0.0%
H: 1.9%
C: 0.47%
authorization treatment risk ema application
Altair and EMA Design Automation Announce Integration of Ultra Librarian into Altair ECAD Verification and Multiphysics Solutions
Published: 2023-09-19 (Crawled : 11:00) - prnewswire.com
ALTR | $82.36 1.97% 1.93% 680K
|
Technology Services
|
| O: -0.21%
H: 0.0%
C: -2.29%
integration solutions ema
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
Published: 2023-09-06 (Crawled : 12:00) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.57%
H: 2.22%
C: -1.01%
fda pharma children achondroplasia positive ema trial
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.95%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: 0.0%
treatment ema
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency
Published: 2023-05-25 (Crawled : 11:00) - globenewswire.com
APLT A | $4.4 -7.17% -7.73% 2.9M
|
Health Technology
|
| O: 2.14%
H: 4.2%
C: -6.29%
at-007 treatment designation ema
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.